Study of AT-527 in Healthy and HCV-Infected Subjects
Status:
Completed
Trial end date:
2018-06-20
Target enrollment:
Participant gender:
Summary
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics
(PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV). In
addition, the study will assess the antiviral activity of AT-527 in subjects infected with
HCV.